Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.

Aledort LM, Navickis RJ, Wilkes MM.

J Thromb Haemost. 2011 Nov;9(11):2180-92. doi: 10.1111/j.1538-7836.2011.04472.x.

2.

Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.

Gruppo RA, Brown D, Wilkes MM, Navickis RJ.

Haemophilia. 2003 May;9(3):251-60. Review.

3.

Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.

Lusher JM.

Haematologica. 2000 Oct;85(10 Suppl):2-5; discussion 5-6. Review.

PMID:
11187864
4.

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.

Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P; ReFacto-AICE Study Group.

Br J Haematol. 2004 Aug;126(3):398-404.

PMID:
15257713
5.

Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.

Rea C, Dunkerley A, Sørensen B, Rangarajan S.

Haemophilia. 2009 Nov;15(6):1237-42. doi: 10.1111/j.1365-2516.2009.02071.x. Epub 2009 Aug 2.

PMID:
19664015
6.
7.
8.
9.

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Calvez T, Chambost H, Claeyssens-Donadel S, d'Oiron R, Goulet V, Guillet B, Héritier V, Milien V, Rothschild C, Roussel-Robert V, Vinciguerra C, Goudemand J; FranceCoag Network.

Blood. 2014 Nov 27;124(23):3398-408. doi: 10.1182/blood-2014-07-586347. Epub 2014 Sep 24.

10.

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.

Hay CR, Palmer BP, Chalmers EA, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Collins PW.

Haemophilia. 2015 Mar;21(2):219-26. doi: 10.1111/hae.12563. Epub 2014 Nov 7.

PMID:
25382829
11.

Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.

Epstein J, Xiong Y, Woo P, Li-McLeod J, Spotts G.

Haemophilia. 2012 Mar;18(2):187-92. doi: 10.1111/j.1365-2516.2011.02636.x. Epub 2011 Aug 24.

PMID:
21883704
12.

Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).

Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.

Haemophilia. 2011 May;17(3):407-11. doi: 10.1111/j.1365-2516.2010.02430.x. Epub 2011 Mar 8.

PMID:
21382134
13.

Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.

Peerlinck K, Hermans C.

Haemophilia. 2006 Nov;12(6):579-90. Review.

PMID:
17083507
14.

Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.

Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A.

J Thromb Haemost. 2013 Sep;11(9):1655-62. doi: 10.1111/jth.12335. Review.

15.

Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII--a robust meta-analytic finding.

Gruppo RA, Brown D, Wilkes MM, Navickis RJ.

Haemophilia. 2004 Sep;10(5):449-51.

PMID:
15357769
16.

Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.

Mancuso ME, Mannucci PM, Rocino A, Garagiola I, Tagliaferri A, Santagostino E.

J Thromb Haemost. 2012 May;10(5):781-90. doi: 10.1111/j.1538-7836.2012.04691.x.

17.

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR.

N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.

18.

Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV.

Biopharm Drug Dispos. 2016 Oct;37(7):409-420. doi: 10.1002/bdd.2023. Epub 2016 Sep 13.

19.

Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.

Delignat S, Dasgupta S, André S, Navarrete AM, Kaveri SV, Bayry J, André MH, Chtourou S, Tellier Z, Lacroix-Desmazes S.

Haematologica. 2007 Oct;92(10):1423-6.

20.

Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.

Yoshioka A, Fukutake K, Takamatsu J, Shirahata A; Kogenate Post-Marketing Surveillance Study Group.

Int J Hematol. 2006 Aug;84(2):158-65.

PMID:
16926139

Supplemental Content

Support Center